Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P1101 vs PEG-Intron in Chronic HCV Genotype 2
NCT04382937Phase 3Completed
- Sponsor
- PharmaEssentia
- Start
- Jan 2016
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of ropeginterferon alfa-2b in hepatitis C (HCV), sponsored by PharmaEssentia. Started Jan 2016; status: completed.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04382937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382937.